Slide 1: CLEAN 3: A first of its kind trial with cost-effectiveness outcomes for peripheral intravenous access
CLEAN 3: A first of its kind trial with cost-effectiveness outcomes for peripheral intravenous access 1, 2 Find out why you should consider using the BD vascular care solutions for all patients requiring a peripheral intravenous catheter (PIVC) for more than 24 hours.
Slide 2: Your guide to the CLEAN 3 Trial
Your guide to the CLEAN 3 Trial Simply navigate directly to the sections you need. Context Clinical outcomes Methodology Strengths and limitations Results Cost-effectiveness analysis Methodology Strengths and limitations Results Summary
Slide 3: About two billion peripheral intravenous catheters are sold annually worldwide
About two billion peripheral intravenous (IV) catheters are sold annually worldwide. 3 Peripheral IV catheter placement is the most common invasive hospital procedure performed worldwide.4 Context 35–50% of peripheral IVs don’t meet their intended Clinical outcomes dwell time, largely due to complic
Slide 4: Catheter-related complications (CRCs): Common, costly and impacting care
Catheter-related complications (CRCs): Common, costly and impacting care Peripheral IV catheter failure may cause: Context Clinical outcomes Methodology Strengths and limitations Results Cost-effectiveness analysis Methodology Strengths and limitations Pain and Vein depletion4 Extended length Additi
Slide 5: You can have a positive impact
You can have a positive impact Improving peripheral vascular care practices can have a positive impact on patients, healthcare providers, hospitals and, more broadly, healthcare systems: Context Implementing best practice policies, may help to reduce Clinical outcomes complications and improve clini
Slide 6: The first large-scale, randomized clinical trial of its kind
CLEAN 3 Trial: The first large-scale, randomized clinical trial of its kind1 Peripheral intravenous catheters (PIVCs) are used extensively within hospitals and sometimes need to be removed prematurely due to complications. Context Yet, until recently, there had not been any large clinical trials Cli
Slide 7: Comparing two peripheral vascular care approaches and the efficacy of two skin antiseptics
CLEAN 3 Trial: Comparing two peripheral vascular care approaches and the efficacy of two skin antiseptics Could an integrated solution extend the time between Could using a different antiseptic catheter insertion and PIVC failure? prevent infectious complications? Context Clinical outcomes BD vascul
Slide 8: A closer look at this pioneering trial
CLEAN 3 Trial: A closer look at this pioneering trial Trial design: An open-label, single center, randomized, controlled, two-by-two factorial trial. Context Clinical outcomes Best practice: Conducted under best practice conditions, Methodology CLEAN 3 involved the peer-to-peer training of all healt
Slide 9: How the results were measured
CLEAN 3 Trial: How the results were measured Outcome 1 Context Incidence of infectious catheter related complications, Clinical outcomes including local infections, catheter colonization and Methodology Strengths and limitations catheter-related bloodstream infections (CR-BSI). Results Cost-effectiv
Slide 10: Strengths
CLEAN 3 Trial: Strengths Context Clinical outcomes Methodology Strengths and limitations 7 Results Cost-effectiveness analysis Methodology Strengths and limitations Training Availability Participation Randomized High number of Results Of all healthcare Of nearly all catheters included Some of clinic
Slide 11: Limitations
CLEAN 3 Trial: Limitations Not all eligible patients were enrolled; emergency room had strain (high demand) periods not suitable for inclusion of patients in study. Blinding was not possible because the two antiseptics differed in color and the devices were easily recognizable, however microbiologis
Slide 12: What it did not show
CLEAN 3 Trial: What it did not show Not part of the study design: Context • Performance/benefit of the individual devices. This study looked at the combination Clinical outcomes of innovative solutions Methodology Strengths and limitations • Any benefit relating to combination of 2% CHG plus 70% IPA
Slide 13: This study showed the BD vascular care solution may improve patient outcomes
This study showed the BD vascular care solution and skin antiseptic* may improve patient outcomes The BD vascular care solution should be considered to the risk of catheter occlusion and dislodgement and increase dwell times. Context 27% 4% vs 9% 92% Clinical outcomes Methodology Strengths and limit
Slide 14: What this means: The new rules for PIVC care
What this means: The new rules for PIVC care 1. The use of an integrated BD vascular care solution should be the rule when the expected PIVC dwell time exceeds 24 hours. Context This system includes: i. A closed integrated peripheral IV catheter Clinical outcomes ii. A positive displacement needle-f
Slide 15: Cost-effectiveness analysis
CLEAN 3 Trial: Cost-effectiveness analysis 2 The innovative bundle approach to peripheral vascular care and skin disinfection solution are more costly than a standard approach, the research question is whether the extra cost is Context offset by the savings generated by less replacements and Clinica
Slide 16: Cost-effectiveness analysis model and scenarios
CLEAN 3 Trial: Cost-effectiveness analysis Methodology: A 14-day time model based on observed data from CLEAN-3 study considering 5 health states (or conditions) and 8 transitional events* (or probabilities of a PIVC to be removed) over cycles of 1.4 days and within the following scenarios: Context
Slide 17: Strengths and limitations
CLEAN 3 Trial: Strengths and limitations Strengths: Context Clinical outcomes Methodology Strengths and limitations This study used the data base from A strong statistical model structure was Results Clean 3 trial, which was randomized and developed including 3 scenarios. Cost-effectiveness analysis
Slide 18: This cost-effectiveness analysis showed significant savings for the hospital
This cost-effectiveness analysis showed that the BD vascular care solution strategy is significantly more effective to prevent PVC-complications, with significant savings for the hospital Context In all scenarios BD vascular care solution is the dominant Clinical outcomes solution (less costly and m
Slide 19: Results
Results Main results, per patient*: RESULTS PER PATIENT Standard approach BD vascular care solution Difference Patients with unscheduled PIVC removal 47.5% 34.8% 12.65% Context Clinical outcomes Base case scenario €144 (€135-€154) €102 (€95-€109) €42 (€32-€54) Methodology Scenario 1 €169 (€160-€179)
Slide 20: Why you should consider using the BD vascular care solution
CLEAN 3 Trial : Why you should 1 consider using the BD vascular care solution for all PIVC patients exceeding 24 hours dwell time Context Clinical outcomes Methodology Peripheral intravenous catheters (PIVCs) Strengths and limitations Results are one of the most commonly used Cost-effectiveness anal
Slide 21: Trial aimed to find out whether
CLEAN 3 Trial aimed to find out whether: Context • The use of an integrated BD vascular care solution extends the time Clinical outcomes between catheter insertion and PIVC failure, compared with Methodology a standard approach. Strengths and limitations Results • Skin preparation with 2% CHG 70% is
Slide 22: This study showed the BD vascular care solution may improve patient outcomes
This study showed that the BD vascular care solution and skin antiseptic* may improve patient outcomes compared with the standard group 4% Context 27% vs 92% €42 Clinical outcomes 9% Methodology Strengths and limitations Results Cost-effectiveness analysis Methodology Reduction in risk of Reduced ca
Slide 23: The new rules for PIVCs
The new rules for PIVCs 1. Consider using a BD vascular care solution, when the expected PIVC dwell time exceeds 24 hours. Context Clinical outcomes 2. A 2% CHG plus 70% IPA single use, sterile applicator should become the first-line antiseptic for skin disinfection prior to Methodology the insertio
Slide 24: We're here for fewer complications
We’re here for fewer complications As a global leader in vascular access solutions, we’re on a mission to make sure every healthcare professional is able to use the right catheter for the right patient at the right time, every time. Context BD Vascular Access Management is an integrated approach des
Slide 25: References
References 1. Guenezan J, Marjanovic N, Drugeon B, et al. Chlorhexidine plus alcohol versus povidone iodine plus alcohol, combined or not with innovative devices, for prevention of short-term peripheral venous catheter infection and failure (CLEAN 3 study): an investigator-initiated, open-label, sin